Cognition Therapeutics Reports Phase 2 Results for Alzheimer's Drug

Author: Benzinga Newsdesk | July 29, 2024 07:05am

Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today reported that participants in the proof-of-concept Phase 2 ‘SHINE' study (NCT03507790) who were treated with CT1812 for six months showed a consistent trend in cognitive improvement compared to placebo across all cognitive measures including ADAS-Cog 11, ADAS-Cog 13, cognitive composite and MMSE. In addition, there were signals of improvement in functional measures (ADCS-ADL and ADCS-CGIC). Details of these clinical and biomarker findings are reported in posters at the Alzheimer's Association's International Conference on July 29, 2024 in Philadelphia, PA.

Posted In: CGTX